Controversies in the use of nevirapine for prevention of mother-to-child transmission of HIV

Bibliography

• JOINT UNITED NATIONS PROGRAMME ON HIV/AIDS (UNAIDS), AND WORLD HEALTH ORGANIZATION: AIDS epidemic update (2004). World Health Organization Geneva, Switzerland (2004).
   Google Scholar
• VERMUND SH: Prevention of mother-to-child transmission of HIV in Africa. Top. HIV Med. (2004) 12:130-134.
   PubMedGoogle Scholar
• MOFENSON LM: Successes and challenges in the perinatal HIV-1 epidemic in the United States as illustrated by the HIV-1 serosurvey of childbearing women. Arch. Pediatr. Adolesc. Med. (2004) 158:422-425.
   PubMedGoogle Scholar
• EUROPEAN COLLABORATIVE STUDY: Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin. Infect. Dis. (2005) 40:458-465.
   PubMed Web of Science ®Google Scholar
• MAGDER LS, MOFENSON L, PAUL ME et al.: Risk factors for in utero and intrapartum transmission of HIV. J. Acquir. Immune Defic. Syndr. (2005) 38:87-95.
   PubMed Web of Science ®Google Scholar
• MCINTYRE J: Preventing mother-to-child transmission of HIV: successes and challenges. BJOG (2005) 112:1196-1203.
   PubMed Web of Science ®Google Scholar
• WORLD HEALTH ORGANIZATION: Prevention of mother-to-child transmission of HIV: Selection and use of nevirapine. WHO/HIV_AIDS/2001.3. WHO/RHR/01.21. World Health Organization, Geneva, Switzerland (2002).
   Google Scholar
• WORLD HEALTH ORGANIZATION. Antiretroviral drugs and the prevention of mother-to-child transmission of HIV infection in resource-limited settings. Recommendations for a public health approach (2005 revision), Geneva, Switzerland (2005).
   Google Scholar
• GUAY L, MUSOKE P, FLEMING T et al.: Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet (1999) 354:795-802.
   PubMed Web of Science ®Google Scholar
• JACKSON JB, MUSOKE P, FLEMING T et al.: Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet (2003) 362:859-868.
   PubMed Web of Science ®Google Scholar
• ESHLEMAN SH, GUAY LA, MWATHA A et al.: Comparison of mother-to-child transmission rates in Ugandan women with subtype A versus D HIV-1 who received single-dose nevirapine prophylaxis: HIV Network For Prevention Trials 012. J. Acquir. Immune Defic. Syndr. (2005) 39:593-597.
   PubMedGoogle Scholar
• Drug could slash rate of perinatal HIV. Nature (1999) 400:304.
   Google Scholar
• LURIE P, WOLFE SM: HIVNET nevirapine trials. Lancet (1999) 354:1816-1817.
   PubMedGoogle Scholar
• NUWAHA FN, KARLIN T, BUYSE DS, WILFERT C: Prevention of mother to child transmission of HIV: from research to action. XIII International AIDS Conference, Barcelona, Spain (2002) Abstract TuPeF5413.
   Google Scholar
• SIDLEY P: HIV drug under review as firm withdraws FDA application. Br. Med. J. (2002) 324:807.
   PubMedGoogle Scholar
• BALETA A: South African government threatens to ban nevirapine. Move would take away option for treating vertical HIV transmission. Lancet (2003) 362:451.
   PubMedGoogle Scholar
• SIDLEY P: South African government to withdraw antiretrovirals for pregnant mothers. Br. Med. J. (2003) 327:306.
   PubMedGoogle Scholar
• CULLINAN K: Court orders South Africa to treat pregnant HIV-positive women with nevirapine. Bull. World Health Organ. (2002) 80:335.
   PubMedGoogle Scholar
• WORLD HEALTH ORGANIZATION: Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. Guidelines on care, treatment and support for women living with HIV/AIDS and their children in resource-constrained settings. World Health Organization, Geneva, Switzerland (2004).
   Google Scholar
• COHEN J: HIV transmission. Allegations raise fears of backlash against AIDS prevention strategy. Science (2004) 306:2168-2169.
   PubMedGoogle Scholar
• INSTITUTE OF MEDICINE: Review of the HIVNET 012 Perinatal HIV Prevention Study. Institute of Medicine, Washington DC, USA (2005).
   Google Scholar
• MIROCHNICK M, FENTON T, GAGNIER P et al.: Pharmacokinetics of nevirapine in human immunodeficiency virus type 1- infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J. Infect. Dis. (1998) 178:368-374.
   PubMed Web of Science ®Google Scholar
• MERLUZZI VJ, HARGRAVE KD, LABADIA M et al.: Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science (1990) 250:1411-1413.
   PubMed Web of Science ®Google Scholar
• HAVLIR D, CHEESEMAN SH, MCLAUGHLIN M et al.: High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J. Infect. Dis. (1995) 171:537-545.
   PubMed Web of Science ®Google Scholar
• MIROCHNICK M, CAPPARELLI E: Pharmacokinetics of antiretrovirals in pregnant women. Clin. Pharmacokinet. (2004) 43:1071-1087.
   PubMed Web of Science ®Google Scholar
• GROB PM, CAO Y, MUCHMORE E et al.: Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase. Nat. Med. (1997) 3:665-670.
   PubMed Web of Science ®Google Scholar
• MOODLEY D, MOODLEY J, COOVADIA H et al.: A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J. Infect. Dis. (2003) 187:725-735.
   PubMed Web of Science ®Google Scholar
• SHERMAN GG, JONES SA, COOVADIA AH, URBAN MF, BOLTON KD: PMTCT from research to reality-results from a routine service. S. Afr. Med. J. (2004) 94:289-292.
   PubMed Web of Science ®Google Scholar
• MARTINSON N, MORRIS L, GREY G et al.: HIV resistance and transmission following single-dose nevirapine in a PMTCT cohort. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA (2004). (2004) Abstract 38 .
   Google Scholar
• QUAGHEBEUR A, MUTUNGA L, MWANYUMBA F, MANDALIYA K, VERHOFSTEDE C, TEMMERMAN M: Low efficacy of nevirapine (HIVNET012) in preventing perinatal HIV-1 transmission in a real-life situation. AIDS (2004) 18:1854-1856.
   PubMedGoogle Scholar
• KIARIE JN, KREISS JK, RICHARDSON BA, JOHN-STEWART GC: Compliance with antiretroviral regimens to prevent perinatal HIV-1 transmission in Kenya. AIDS (2003) 17:65-71.
   PubMed Web of Science ®Google Scholar
• STRINGER JS, SINKALA M, CHAPMAN V et al.: Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine. AIDS (2003) 17:1659-1665.
   PubMed Web of Science ®Google Scholar
• STRINGER JS, SINKALA M, GOLDENBERG RL et al.: Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings. AIDS (2004) 18:939-943.
   PubMed Web of Science ®Google Scholar
• AYOUBA A, TENE G, CUNIN P et al.: Low rate of mother-to-child transmission of HIV-1 after nevirapine intervention in a pilot public health programme in Yaounde, Cameroon. J. Acquir. Immune Defic. Syndr. (2003) 34:274-280.
   PubMed Web of Science ®Google Scholar
• KAGAAYI J, DREYFUSS ML, KIGOZI G et al.: Maternal self-medication and provision of nevirapine to newborns by women in Rakai, Uganda. J. Acquir. Immune Defic. Syndr. (2005) 39:121-124.
   PubMed Web of Science ®Google Scholar
• GREY GE, URBAN M, CHERSICH MF et al.: A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers. AIDS (2005) 19:1289-1297.
   PubMedGoogle Scholar
• TAHA TE, KUMWENDA NI, HOOVER DR et al.: Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial. JAMA (2004) 292:202-209.
   PubMed Web of Science ®Google Scholar
• LALLEMANT M, JOURDAIN G, LE COEUR S et al.: Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N. Engl. J. Med. (2004) 351:217-228.
   PubMed Web of Science ®Google Scholar
• SHAPIRO R, THIOR I, GILBERT P et al.: Maternal single-dose nevirapine may not be needed to reduce mother-to-child HIV transmission in the setting of maternal and infant zidovudine and infant single-dose nevirapine: results of a randomised clinical trial in Botswana. 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA (2005) Abstract 74LB .
   Google Scholar
• TAHA TE, KUMWENDA NI, GIBBONS A et al.: Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial. Lancet (2003) 362:1171-1177.
   PubMed Web of Science ®Google Scholar
• DABIS F, BEQUET L, EKOUEVI DK et al.: Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS (2005) 19:309-318.
   PubMed Web of Science ®Google Scholar
• CRESSEY TR, JOURDAIN G, LALLEMANT MJ et al.: Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. J. Acquir. Immune Defic. Syndr. (2005) 38:283-288.
   PubMed Web of Science ®Google Scholar
• ESHLEMAN SH, JONES D, GUAY L et al.: HIV-1 variants with diverse nevirapine resistance mutations emerge rapidly after single dose nevirapine: HIVNET 012. XII International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications. Cabo San Lucas, Mexico (2003).
   Google Scholar
• ESHLEMAN SH, GUAY LA, MWATHA A et al.: Extended analysis of nevirapine (NVP) resistance in women with subtype A versus D 6-8 weeks after single dose NVP prophylaxis: HIVNET 012. 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA (2003) Abstract P40 (857).
   Google Scholar
• ESHLEMAN SH, HOOVER DR, CHEN S et al.: Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J. Infect. Dis. (2005) 192:30-36.
   PubMed Web of Science ®Google Scholar
• CHAIX ML, MONTCHO C, EKOUEVI DK et al.: Genotypic resistance analysis in women who received intrapartum nevirapine associated to a short course of zidovudine to prevent perinatal HIV-1 transmission: the ditrame plus ANRS 1201/02 study, Abidjan, Côte d’Ivoire. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA (2004) Abstract 457.
   Google Scholar
• ESHLEMAN SH, JACKSON JB: Nevirapine resistance after single dose prophylaxis. AIDS Rev. (2002) 4:59-63.
   PubMedGoogle Scholar
• ESHLEMAN SH, HOOVER D, CHEN S et al.: Comparison of nevirapine resistance in women with subtype C compared with subtypes A and D after single-dose NVP. 12th Conference on Retroviruses and Oppotunistic Infections, Boston, MA, USA (2005) Abstract 799.
   Google Scholar
• ESHLEMAN SH, GUAY LA, WANG J et al.: Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A versus D after single-dose nevirapine: HIVNET 012. J. Acquir. Immune Defic. Syndr. (2005) 40:24-29.
   PubMedGoogle Scholar
• MORRIS L, MARTINSON N, PILLAY C et al.: Persistence of nevirapine resistance mutations 6 months following single dose nevirapine. 15th International AIDS Conference, Bangkok, Thailand (2004).
   Google Scholar
• LEE EJ, KANTOR R, ZIJENAH L et al.: Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine. J. Infect. Dis. (2005) 192:1260-1264.
   PubMedGoogle Scholar
• CHAIX ML, DABIS F, EKOUEVI D et al.: Addition of 3 days of ZDV+3TC postpartum to a short course of ZDV+3TC and single-dose NVP provides low rate of NVP resistance mutations and high efficacy in preventing peri-partum HIV-1 transmission: ANRS DITRAME Plus, Abidjan, Côte d’Ivoire. 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA (2005) Abstract 72LB.
   Google Scholar
• JOURDAIN G, NGO-GIANG-HUONG N, LE COEUR S et al.: Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N. Engl. J. Med. (2004) 351:229-240.
   PubMed Web of Science ®Google Scholar
• LYONS FE, COUGHLAN S, BYRNE CM, HOPKINS SM, HALL WW, MULCAHY FM: Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. AIDS (2005) 19:63-67.
   PubMed Web of Science ®Google Scholar
• ESHLEMAN SH, MRACNA M, GUAY LA et al.: Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS (2001) 15:1951-1957.
   PubMed Web of Science ®Google Scholar
• SULLIVAN J, THE SAINT STUDY TEAM: South African Intrapartum Nevirapine Trial (SAINT): selection of resistant mutations. XIV International AIDS Conference, Barcelona, Spain (2002) Abstract LbPeB902.
   Google Scholar
• HAMMER SM: Single-dose nevirapine and drug resistance: the more you look, the more you find. J. Infect. Dis. (2005) 192:1-3.
   PubMedGoogle Scholar
• JOHNSON JA, LI JF, MORRIS L et al.: Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J. Infect. Dis. (2005) 192:16-23.
   PubMed Web of Science ®Google Scholar
• PALMER S, BOLTZ V, MALDARELLI F et al.: Persistence of NNRTI-r resistant variants after single-dose nevirapine in HIV-1 subtype-C-infected women. 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA (2005) Abstract 101.
   Google Scholar
• FLYS T, NISSLEY DV, CLAASEN CW et al.: Sensitive drug resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J. Infect. Dis. (2005) 192:24-29.
   PubMedGoogle Scholar
• MARTINSON N, LUPONDWANA P, MORRIS L et al.: Effectiveness of single dose nevirapine in a second pregnancy. 12th Conference on Retroviruses and Opportunbistic Infections, Boston, MA, USA (2005) Abstract 103.
   Google Scholar
• ZIJENAH L, KADZIRANGE G, RUSAKANIKO S et al.: Community-based generic antiretroviral therapy following single-dose nevirapine or short-course AZT in Zimbabwe. 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA (2005) Abstract 632.
   Google Scholar
• BEDIKOU G, VIHO I, TONWE-GOLD B et al.: 6-Month immunological response with HAART containing nevirapine in HIV infected women post exposure to single dose of nevirapine for PMTCT. The MTCT-plus initiave in Abidjan, Côte d’Ivoire (2003-2005). 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil (2005) Abstract MoOa0203.
   Google Scholar
• LOCKMAN S, SMEATON L, SHAPIRO R et al.: Maternal and infant response to nevirapine (NVP)-based antiretroviral treatment (ART) following peripartum single-dose NVP or placebo (Plc). 43rd Annual Meeting of IDSA, San Francisco, CA, USA. (2005) Abstract LB5. Available at www.idsociety.org .
   Google Scholar
• MCINTYRE JA, MARTINSON N, GREY GE et al.: Addition of short course combivir to single dose viramune for the prevention of mother to child transmission of HIV-1 can significantly decrease the subsequent development of maternal and paediatric NNRTI-resistant virus. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil (2005) Abstract TuFoO2O4.
   Google Scholar
• PALMER S, BOLTZ V, MALDERELLI F et al.: Short-course combivir (CBV) single dose nevirapine reduces but does not eliminate the selection of nevirapine-resistant HIV-1: improved detection by allele-specific PCR. XIV International HIV Drug Resistance Workshop: Basic Principles And Clinical Implications, Quebéc, Canada. (2005) Abstract 3. Antiviral therapy 10:S5 Available at http://www.intmedpress.com/files/PDF/Session1FINAL.pdf.
   Google Scholar
• US PUBLIC HEALTH SERVICE: Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States.Washington DC, USA (2005).
   Google Scholar
• THE BRITISH HIV ASSOCIATION: Guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmission of HIV. The British HIV Association, London, UK (2005).
   Google Scholar
• HITTI J, FRENKEL LM, STEK AM et al.: Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J. Acquir. Immune Defic. Syndr. (2004) 36:772-776.
   PubMed Web of Science ®Google Scholar
• TIMMERMANS S, TEMPELMAN C, GODFRIED MH et al.: Nelfinavir and nevirapine side effects during pregnancy. AIDS (2005) 19:795-799.
   PubMed Web of Science ®Google Scholar
• MONEY D, KHOO D, MACDONALD G et al.: A comparison of toxicity in nevirapine- versus protease inhibitor-containing HAART regimens in pregnant women. 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA (2005) Abstract 784.
   Google Scholar
• NATARAJAN U, PYM A, ANDERSON J et al.: The side effect profile associated with use of nevirapine in a cohort of pregnant women in London. 7th Conference on HIV Drug Therapy, Glasgow, Scotland (2004) Abstract P190.
   Google Scholar
• BERSHOFF-MATCHA SJ, MUNDY LM, HENRY JV: Adverse events to nevirapine therapy during pregnancy. 11th Conference on Retroviruses and Opportunisitc Infections, San Francisco, CA, USA (2004) Abstract 939.
   Google Scholar
• PHANUPHAK N, APORNPONG T, INTARASUK S, TEERATAKULPISARN S, PHANUPHAK P: Toxicities from nevirapine in HIV-infected males and females, including pregnant females with various CD4 cell counts. 12th Conference on Retroviruses and Opprtunistic Infections, Boston, MA, USA (2005) Abstract 21.
   Google Scholar
• THOMAS T, AMORNKUL P, MWIDAU J et al.: Preliminary findings: incidence of serious adverse events attributed to nevirapine among women enrolled in an ongoing trial using HAART to prevent mother-to-child HIV transmission. 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA (2005) Abstract 809.
   Google Scholar
• LEITH J, PILIERO P, STORFER S, MAYERS D, HINZMANN R: Appropriate use of nevirapine for long-term therapy. J. Infect. Dis. (2005) 192:545-546.
   PubMedGoogle Scholar
• FDA: FDA Public Health Advisery for nevirapine (viramune). Washington DC, WA, USA (2005).
   Google Scholar